ArticleJACC. Case reports2026
Emergency Transcatheter Aortic Valve Replacement in Cardiogenic Shock Caused by Severe Bicuspid Aortic Valve Stenosis.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment of severe aortic stenosis in cardiogenic shock remains challenging, particularly in younger patients with bicuspid valve stenosis (BVS). CASE SUMMARY: A 51-year-old woman with severe high-gradient BVS presented in cardiogenic shock with multiorgan dysfunction. Given hemodynamic instability, the heart team proceeded with urgent transcatheter aortic valve replacement. A 26-mm balloon-expandable Edwards SAPIEN 3 Ultra RESILIA valve was successfully implanted, resulting in rapid hemodynamic stabilization. DISCUSSION: This case highlights the importance of urgent heart team decision-making in unstable patients with severe BVS. Lifetime management requires individualized device selection considering annular dimensions, calcification pattern, coronary access, and future redo-procedure strategies. TAKE-HOME MESSAGES: In the presence of refractory cardiogenic shock, transcatheter aortic valve replacement may be the preferred treatment strategy and should be considered as part of an individualized lifetime management strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.